Novel BCL6-targeting proteolysis-targeting chimeras (PROTACs) with effective antitumor activities against DLBCL in vitro and in vivo have been identified, and could be tested in human trials in the future [45]. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.